These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6985855)

  • 41. A selective method for determination of methylguanidine in biological fluids. Its application in normal subjects and uremic patients.
    Eksborg S; Persson BA; Allgen LG; Bergström J; Zimmerman L; Fürst P
    Clin Chim Acta; 1978 Jan; 82(1-2):141-50. PubMed ID: 618677
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes in the electroencephalogram in acute uremia. Effects of parathyroid hormone and brain electrolytes.
    Guisado R; Arieff AI; Massry SG; Lazarowitz V; Kerian A
    J Clin Invest; 1975 Apr; 55(4):738-45. PubMed ID: 235562
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Calcium metabolism of brain in acute renal failure. Effects of uremia, hemodialysis, and parathyroid hormone.
    Arieff AI; Massry SG
    J Clin Invest; 1974 Feb; 53(2):387-92. PubMed ID: 11344551
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Assessment of urea and other uremic markers for quantification of dialysis efficacy.
    Vanholder RC; De Smet RV; Ringoir SM
    Clin Chem; 1992 Aug; 38(8 Pt 1):1429-36. PubMed ID: 1643710
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors.
    Sjöholm I; Kober A; Odar-Cederlöf I; Borgåa O
    Biochem Pharmacol; 1976 May; 25(10):1205-13. PubMed ID: 938543
    [No Abstract]   [Full Text] [Related]  

  • 46. Differences in the distribution of urea and creatinine between red cells and plasma in normal and azotemic blood as assessed by autoanalyzer and manual chemical methods.
    Nolph K; Felts J; Moore R; Van Stone J
    Int Urol Nephrol; 1978; 10(1):59-64. PubMed ID: 649287
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phenylacetylglutamine and hippuric acid in uremic and healthy subjects.
    Zimmerman L; Jörnvall H; Bergström J
    Nephron; 1990; 55(3):265-71. PubMed ID: 2370926
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid.
    Barré J; Chamouard JM; Houin G; Tillement JP
    Clin Chem; 1985 Jan; 31(1):60-4. PubMed ID: 3917383
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elimination and serum protein binding of phenylbutazone in patients with renal insufficiency.
    Held H; Enderle C
    Clin Nephrol; 1976 Sep; 6(3):388-93. PubMed ID: 136326
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of in vivo and in vitro dialysis on plasma transaminase activity.
    Crawford DR; Reyna RS; Weiner MW
    Nephron; 1978; 22(4-6):418-22. PubMed ID: 740106
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma calcium fraction dynamics in uremic patients undergoing hemodialysis.
    Asad SN; Olmer AJ; Letteri JM
    Miner Electrolyte Metab; 1984; 10(5):333-6. PubMed ID: 6493162
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Protein binding of ceftriaxone: comparison of three techniques of determination and the effect of 2-hydroxybenzoylglycine, a drug-binding inhibitor in uremia.
    Fiset C; Vallée F; LeBel M; Bergeron MG
    Ther Drug Monit; 1986; 8(4):483-9. PubMed ID: 3824437
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of disease on binding of drugs to plasma proteins.
    Reidenberg MM; Affrime M
    Ann N Y Acad Sci; 1973 Nov; 226():115-26. PubMed ID: 4520390
    [No Abstract]   [Full Text] [Related]  

  • 54. Skin bleeding time for the evaluation of uremic platelet dysfunction and effect of dialysis.
    Soyoral YU; Demir C; Begenik H; Esen R; Kucukoglu ME; Aldemir MN; Demirkiran D; Erkoc R
    Clin Appl Thromb Hemost; 2012; 18(2):185-8. PubMed ID: 22327827
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The effect of endogenous compounds, isolated from sera of uremic patients, on chloramphenicol binding to proteins.
    Grafnetterová J; Grafnetter D; Schück O; Tomková D; Bláha J
    Biochem Pharmacol; 1979 Oct; 28(19):2923-8. PubMed ID: 518688
    [No Abstract]   [Full Text] [Related]  

  • 56. Distribution of sodium valproate in normal whole blood and in blood from patients with renal or hepatic disease.
    Shirkey RJ; Jellett LB; Kappatos DC; Maling TJ; Macdonald A
    Eur J Clin Pharmacol; 1985; 28(4):447-52. PubMed ID: 3928388
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Correction of drug binding defects in uremia in vitro by anion exchange resin treatment.
    Lichtenwalner DM; Suh B; Lorber B; Rudnick MR; Craig WA
    Biochem Pharmacol; 1982 Nov; 31(21):3483-7. PubMed ID: 7150368
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Binding affinity and capacity for the uremic toxin indoxyl sulfate.
    Devine E; Krieter DH; Rüth M; Jankovski J; Lemke HD
    Toxins (Basel); 2014 Jan; 6(2):416-29. PubMed ID: 24469432
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protein binding of salicylate in uremic and normal plasma.
    Borgå O; Cederlöf IO; Ringberger VA; Norlin A
    Clin Pharmacol Ther; 1976 Oct; 20(4):464-75. PubMed ID: 975718
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Study on the assay of uremic protein-binding inhibitors: furan compound and hippuric acid].
    Tanaka Y
    Nihon Jinzo Gakkai Shi; 1991 Jul; 33(7):643-51. PubMed ID: 1749115
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.